Table 1.
Clinical characteristics of included patients.
| *Variable | Total | Control | Bronchitis | ABPA | Pneumonia | P-value |
|---|---|---|---|---|---|---|
| Number of patients, n | 109 | 63 | 22 | 18 | 6 | |
| Age, years, median (range) | 26.0 (6–69) | 27.0 (6–69) | 26.0 (8.0–57.0) | 21.5 (9.0–49.0) | 30.5 (15.0–43.0) | ns |
| Female sex, n (%) | 62 (56.9%) | 37 (58.7%) | 14 (63.6%) | 9 (50.0%) | 2 (33.3%) | ns |
| CFTR dF508 homozygous, n (%) | 49 (45.0%) | 26 (41.3%) | 12 (54.5%) | 8 (44.4%) | 3 (50.0) | ns |
| BMI, kg/m2, median (range) | 19.8 (12.4–34.2) | 20.2 (12.4–34.2) | 20.2 (14.5–29.5) | 18.8 (14.6–26.9) | 17.5 (15.3–23.5) | ns |
| Percent-predicted FEV1, median (range) | 54.0 (16.0–133.1) | 60.0 (17.0–133.1) | 41.0 (16.3–96.6) | 60.0 (27.0–90.0) | 22.0 (16.0–57.0) | <0.01 |
| Diabetes, n (%) | 27 (24.8%) | 12 (19.1%) | 6 (27.3%) | 5 (27.8%) | 4 (66.7%)00 | ns |
| Pancreatic insufficiency, n (%) | 100 (91.7%) | 57 (90.5%) | 20 (90.9%) | 17 (94.4%) | 6 (100%) | ns |
| Total IgG, kU/L, median (range) | 13.2 (2.0–73.0) | 13.2 (6.0–73.0) | 12.3 (2.0–21.9) | 13.6 (6.2–25.2) | 16.3 (13.0–22.0) | ns |
| Gm3, mg/L, median (range) | 60.0 (3.0–200) | 48.9 (2.7–200) | 51.2 (18.2–145) | 97.5 (24.2–200) | 95.3 (78.2–140) | <0.01 |
| Gm3 > 39 mg/L, n (%) |
72 (66,1) | 37 (58,7) | 15 (68,2) | 14 (77,8) | 6 (100) | |
| Total IgE, kU/L, median (range) | 34.5 (2.0–4359) | 26.5 (2.5–199) | 30.2 (2.1–262) | 1048 (344–4359) | 44.4 (2.0–84.5) | <0.01 |
| Aspergillus specific IgE, kU/L, median (range) | 0.1 (0.1–51.7) | 0.1 (0.1–0.1) | 0.1 (0.1–3.2) | 25.7 (10.8–51.7) | 0.1 (0.1–1.0) | <0.01 |
| Steroids, n (%) | 17 (15.6%) | 0 (0%) | 8 (36.4%) | 7 (38.9%) | 2 (33.3%) | <0.01 |
| Antifungal treatment (Caspofungin, Itraconazole, Posaconazole), n (%) | 8 (7.3%) | 0 (0%) | 2 (9.1%) | 5 (27.8%) | 1 (16.7%) | <0.01 |
| Chronic Pseudomonas aeruginosa, n (%) | 71 (65.1%) | 37 (58.7%) | 17 (77.3%) | 13 (72.2%) | 4 (66.7%) | ns |
| Aspergillus fumigatus positive sputum, n (%) | 45 (41.3%) | 21 (33.3%) | 17 (77.3%) | 5 (27.8%) | 2 (33.3%) | <0.01 |
| Aspergillus PCR positive, n (%), n (%) | 60 (55.0%) | 30 (47.6%) | 16 (72.7%) | 12 (66.7%) | 2 (33.3%) | ns |
| Candida spp. positive sputum, n (%) | 93 (85.3%) | 53 (84.1%) | 20 (90.9%) | 15 (83.3%) | 5 (83.3%) | ns |
| Detection of other fungal pathogens*, n (%) | 12 (11.0%) | 6 (9.5%) | 5 (22.7%) | 1 (5.6%) | 0 (0%) | ns |
*Except Candida and Aspergillus species.